3 days popular7 days popular1 month popular3 months popular

Results Of PARTNER Cohort B Trial Presented At TCT 2012: Benefits Of Transcatheter Aortic Valve Replacement Over 3 Years

A study found that transcatheter (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional . Results of the PARTNER Cohort B trial were presented at the 24th annual () scientific symposium. Sponsored by the (CRF), TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

TAVR is the recommended treatment for patients with severe who are not suitable candidates for surgery. Outcomes beyond two years in such patients have not yet been extensively studied.

Inoperable patients with severe symptomatic aortic stenosis (AS) were randomly assigned to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty) in the PARTNER trial. Data on three-year outcomes were analyzed according to intention to treat (ITT).

A total of 358 patients underwent randomization at 21 centers. The Kaplan Meier estimated rates of death at three years were 54.1 percent in the TAVR group and 80.9 percent in the standard-therapy group (P<0.0001); corresponding rates of cardiac death were 41.4 percent and 74.5 percent (P<0.0001). The survival advantage associated with TAVR that was initially observed at one year persisted during the subsequent years.

“After three years of follow-up, the benefits of TAVR were sustained as measured by all cause mortality, cardiovascular mortality, repeat hospitalization, and functional status,” said one of the investigators, E. Murat Tuzcu, MD. Dr. Tuzcu is Professor of Medicine and Vice-Chairman of the Department of Cardiology in the Sydell and Arnold Heart & Vascular Institute at the Cleveland Clinic.

“Three-year data continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates,” said Dr. Tuzcu.

Source

The trial was funded by Edwards Lifesciences. Dr. Tuzcu reported no financial conflicts of interest.
Cardiovascular Research Foundation